Micro Imaging Technology Announces a Date for Its Annual General Shareholders Meeting

SAN CLEMENTE, CA--(Marketwire - Oct 12, 2011) - Micro Imaging Technology, Inc. (OTCBB: MMTC) (OTCQB: MMTC) announced today that the Company's Annual General Meeting of Shareholders will be held at MIT's offices located at 970 Calle Amanecer, Suite F, San Clemente, CA 92673 on Wednesday, November 30, 2011 at 10:00 AM (PST) following the U.S. Securities and Exchange Commission ("SEC") approval of its October 11, 2011 Schedule 14A Filing -- Information Required in a Proxy Statement. Although there will be a mailing to all shareholders of record including a Proxy Ballot by the Company's transfer agent, American Stock Transfer and Trust ("AST&T"), the complete Proxy Statement and Annual Report on Form 10-K/A (Amendment No. 1) can be viewed at the Company's web site www.micro-imaging.com or within MMTC's 14A filing with the SEC; referencing MMTC: www.sec.gov.

The Company is asking its shareholders to vote on two proposals:

1) To elect two (2) Directors to the Company's Board of Directors, each to serve a term of one year and until their respective successors have been elected and qualified, or until their earlier resignation or removal. The Board of Directors has nominated for election to the Board: Michael W. Brennan and Victor A. Hollander, respectively the Company's Chairman and Chief Financial Officer; and the second and third largest shareholder.

2) To approve an amendment to the Company's Articles of Incorporation increasing the total number of authorized shares from 500,000,000 to 2,500,000,000.

With respect to the election of two Directors, Chairman Michael Brennan stated that, "Over the course of the next several months the Company is committed to increasing the size of the Board by adding at least two new Directors which will assist in guiding the Company as it enters its production stage."

Commenting on the request to increase the authorized number of shares, the Company's Chief Financial Officer Victor Hollander noted that, "The Company's development stage, which commenced in November 2005, has required almost $16 million in funding which has been provided from a variety of equity sources, including continual purchases of Common Stock by the Company's three largest shareholders. Consequently, as we prepare to launch our products in a $5 billion market, we must in the near term still be reliant on equity funding."

ABOUT MICRO IDENTIFICATION TECHNOLOGIES:
MIT is a California-based public company that has developed and patented a Microbial Identification System that revolutionizes the pathogenic bacteria diagnostic process and can annually save thousands of lives and tens of millions of dollars in health care costs. The System identifies bacteria in minutes, not days, and at a significant per test cost savings when compared to any other conventional method. It does not rely on chemical or biological agents, conventional processing, fluorescent tags, gas chromatography or DNA analysis. The process requires only clean water and a sample of the unknown bacteria. Revenues for all rapid testing methods exceed $5 billion annually -- with food safety accounting for over $3.5 billion, which is expected to surpass $4.7 billion by 2015, according to BCC Research. In addition, the recently passed "New" U.S. Food Safety Bill is expected to further accelerate the current annual growth rate of 6.6 percent.

MIT previously completed an extensive evaluation by the AOAC RI Institute which included rigorous independent testing and thorough reviews by its expert examiners, including the U.S. Department of Agriculture. The AOAC RI Report is available from the Company. www.aoac.org

MIT also demonstrated the ability to detect and identify, within several minutes, the microbes Escherichia coli, Listeria, Salmonella, Staphylococcus aureus, and other pathogenic bacteria. MIT recently performed over 300 tests for the identification of these contaminants and scored 95% accuracy. The System can currently identify 23 species of bacteria and its capabilities are easily expanded. The identification process has also been verified by North American Science Associates, Inc. ("NAMSA"), an independent and internationally recognized bioscience testing laboratory. The NAMSA Test Report is available from the Company and, in MIT's opinion, demonstrates the accuracy, speed and cost effectiveness of the System over conventional processes. www.namsa.com

This release contains statements that are forward-looking in nature. Statements that are predictive in nature, that depend upon or refer to future events or conditions or that include words such as "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions are forward-looking statements. These statements are made based upon information available to the Company as of the date of this release, and we assume no obligation to update any such forward-looking statements. These statements are not guarantees of future performance and actual results could differ materially from our current expectations. Factors that could cause or contribute to such differences include, but are not limited to dependence on suppliers; short product life cycles and reductions in unit selling prices; delays in development or shipment of new products; lack of market acceptance of our new products or services; inability to continue to develop competitive new products and services on a timely basis; introduction of new products or services by major competitors; our ability to attract and retain qualified employees; inability to expand our operations to support increased growth; and declining economic conditions, including a recession. These and other factors and risks associated with our business are discussed from time to time within our filings with the U.S. Securities and Exchange Commission, reference MMTC: www.sec.gov.